Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Principia Biopharma Inc. (PRNB) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Principia Biopharma Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1510487.
Total stock buying since 2018: $69,399,714.
Total stock sales since 2018: $53,365,955.
Total stock option exercises since 2018: $1,097,839.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2020 | 0 | $0 | 141,508 | $10,169,760 | 114,179 | $1,029,916 |
| 2019 | 1,381,884 | $39,224,714 | 1,350,500 | $43,196,195 | 20,505 | $67,923 |
| 2018 | 1,775,000 | $30,175,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2020-09 | 0 | $0 | 5,000 | $499,920 | 5,000 | $29,975 |
| 2020-08 | 0 | $0 | 28,500 | $2,780,677 | 28,500 | $397,569 |
| 2020-07 | 0 | $0 | 22,500 | $1,651,065 | 22,500 | $390,615 |
| 2020-06 | 0 | $0 | 25,504 | $1,562,717 | 20,000 | $68,590 |
| 2020-05 | 0 | $0 | 21,000 | $1,299,384 | 19,175 | $69,065 |
| 2020-03 | 0 | $0 | 25,504 | $1,456,038 | 10,504 | $48,619 |
| 2020-02 | 0 | $0 | 13,500 | $919,959 | 8,500 | $25,483 |
| 2019-12 | 0 | $0 | 40,500 | $2,122,285 | 10,505 | $49,303 |
| 2019-11 | 55,000 | $1,646,700 | 10,000 | $323,910 | 10,000 | $18,620 |
| 2019-10 | 1,326,884 | $37,578,014 | 0 | $0 | 0 | $0 |
| 2019-08 | 0 | $0 | 300,000 | $10,500,000 | 0 | $0 |
| 2019-05 | 0 | $0 | 1,000,000 | $30,250,000 | 0 | $0 |
| 2018-09 | 1,775,000 | $30,175,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-09-18 | Hardiman Roy C. (Chief Business Officer) | Sale | 5,000 | 99.98 | 499,920 |
| 2020-09-18 | Hardiman Roy C. (Chief Business Officer) | Option Ex | 5,000 | 6.00 | 29,975 |
| 2020-08-18 | Thomas Dolca (Chief Medical Officer) | Sale | 15,000 | 100.00 | 1,500,000 |
| 2020-08-18 | Thomas Dolca (Chief Medical Officer) | Option Ex | 15,000 | 23.77 | 356,550 |
| 2020-08-18 | Chai Christopher Y (Chief Financial Officer) | Sale | 7,500 | 99.36 | 745,237 |
| 2020-08-18 | Chai Christopher Y (Chief Financial Officer) | Option Ex | 7,500 | 3.00 | 22,485 |
| 2020-08-10 | Goldstein David M (Chief Scientific Officer) | Sale | 6,000 | 89.24 | 535,440 |
| 2020-08-10 | Goldstein David M (Chief Scientific Officer) | Option Ex | 6,000 | 3.09 | 18,534 |
| 2020-07-15 | Thomas Dolca (Chief Medical Officer) | Sale | 15,000 | 80.07 | 1,201,065 |
| 2020-07-15 | Thomas Dolca (Chief Medical Officer) | Option Ex | 15,000 | 23.77 | 356,550 |
| 2020-07-01 | Colowick Alan (Director) | Sale | 7,500 | 60.00 | 450,000 |
| 2020-07-01 | Colowick Alan (Director) | Option Ex | 7,500 | 4.54 | 34,065 |
| 2020-06-23 | Babler Martin (President, CEO) | Sale | 15,000 | 61.51 | 922,605 |
| 2020-06-23 | Babler Martin (President, CEO) | Option Ex | 15,000 | 3.00 | 44,970 |
| 2020-06-15 | Wolff Stefani (Chief Development Officer) | Sale | 5,504 | 60.69 | 334,037 |
| 2020-06-12 | Hardiman Roy C. (Chief Business Officer) | Sale | 5,000 | 61.22 | 306,075 |
| 2020-06-12 | Hardiman Roy C. (Chief Business Officer) | Option Ex | 5,000 | 4.72 | 23,620 |
| 2020-05-19 | Chai Christopher Y (Chief Financial Officer) | Sale | 7,500 | 65.10 | 488,265 |
| 2020-05-19 | Chai Christopher Y (Chief Financial Officer) | Option Ex | 5,675 | 3.00 | 17,013 |
| 2020-05-07 | Goldstein David M (Chief Scientific Officer) | Sale | 6,000 | 60.18 | 361,062 |
| 2020-05-07 | Goldstein David M (Chief Scientific Officer) | Option Ex | 6,000 | 3.00 | 17,988 |
| 2020-05-05 | Colowick Alan (Director) | Sale | 6,660 | 60.00 | 399,600 |
| 2020-05-05 | Colowick Alan (Director) | Option Ex | 6,660 | 4.54 | 30,249 |
| 2020-05-01 | Colowick Alan (Director) | Sale | 840 | 60.07 | 50,457 |
| 2020-05-01 | Colowick Alan (Director) | Option Ex | 840 | 4.54 | 3,815 |
| 2020-03-16 | Wolff Stefani (Chief Development Officer) | Sale | 5,504 | 46.04 | 253,393 |
| 2020-03-16 | Wolff Stefani (Chief Development Officer) | Option Ex | 5,504 | 4.54 | 24,999 |
| 2020-03-13 | Hardiman Roy C. (Chief Business Officer) | Sale | 5,000 | 49.57 | 247,850 |
| 2020-03-13 | Hardiman Roy C. (Chief Business Officer) | Option Ex | 5,000 | 4.72 | 23,620 |
| 2020-03-03 | Babler Martin (President, CEO) | Sale | 15,000 | 63.65 | 954,795 |
| 2020-02-18 | Chai Christopher Y (Chief Financial Officer) | Sale | 7,500 | 66.41 | 498,045 |
| 2020-02-18 | Chai Christopher Y (Chief Financial Officer) | Option Ex | 2,500 | 3.00 | 7,495 |
| 2020-02-10 | Goldstein David (Chief Scientific Officer) | Sale | 6,000 | 70.32 | 421,914 |
| 2020-02-10 | Goldstein David (Chief Scientific Officer) | Option Ex | 6,000 | 3.00 | 17,988 |
| 2019-12-19 | Thomas Dolca (Chief Medical Officer) | Sale | 495 | 60.00 | 29,700 |
| 2019-12-18 | Babler Martin (President, CEO) | Sale | 4,500 | 53.58 | 241,119 |
| 2019-12-17 | Babler Martin (President, CEO) | Sale | 25,000 | 53.24 | 1,330,950 |
| 2019-12-16 | Wolff Stefani (Chief Development Officer) | Sale | 5,505 | 49.58 | 272,926 |
| 2019-12-16 | Wolff Stefani (Chief Development Officer) | Option Ex | 5,505 | 4.54 | 25,003 |
| 2019-12-13 | Hardiman Roy C. (Chief Business Officer) | Sale | 5,000 | 49.52 | 247,590 |
| 2019-12-13 | Hardiman Roy C. (Chief Business Officer) | Option Ex | 5,000 | 4.86 | 24,300 |
| 2019-11-20 | Becker Daniel J. (Director) | Buy | 55,000 | 29.94 | 1,646,700 |
| 2019-11-07 | Goldstein David (Chief Scientific Officer) | Sale | 10,000 | 32.39 | 323,910 |
| 2019-11-07 | Goldstein David (Chief Scientific Officer) | Option Ex | 10,000 | 1.86 | 18,620 |
| 2019-10-29 | Becker Daniel J. (Director) | Buy | 9,196 | 33.98 | 312,480 |
| 2019-10-28 | Becker Daniel J. (Director) | Buy | 68,404 | 33.41 | 2,285,582 |
| 2019-10-18 | Becker Daniel J. (Director) | Buy | 535,000 | 28.00 | 14,980,000 |
| 2019-10-18 | George Simeon (Director) | Buy | 357,142 | 28.00 | 9,999,976 |
| 2019-10-18 | Glaxosmithkline Plc | Buy | 357,142 | 28.00 | 9,999,976 |
| 2019-08-13 | New Leaf Bpo Management Ii, L.l.c (10% Owner) | Sale | 300,000 | 35.00 | 10,500,000 |
| 2019-05-21 | Orbimed Capital Gp Iv Llc | Sale | 1,000,000 | 30.25 | 30,250,000 |
| 2018-09-18 | Becker Daniel J. (Director) | Buy | 270,000 | 17.00 | 4,590,000 |
| 2018-09-18 | New Leaf Bpo Management Ii, L.l.c (10% Owner) | Buy | 270,000 | 17.00 | 4,590,000 |
| 2018-09-18 | George Simeon (Director) | Buy | 270,000 | 17.00 | 4,590,000 |
| 2018-09-18 | Mehra Anand (10% Owner) | Buy | 270,000 | 17.00 | 4,590,000 |
| 2018-09-18 | Orbimed Capital Gp Iv Llc (10% Owner) | Buy | 250,000 | 17.00 | 4,250,000 |
| 2018-09-18 | Akkaraju Srinivas (Director) | Buy | 175,000 | 17.00 | 2,975,000 |
| 2018-09-18 | Glaxosmithkline Plc | Buy | 270,000 | 17.00 | 4,590,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of PRNB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Principia Biopharma Inc. (symbol PRNB, CIK number 1510487) see the Securities and Exchange Commission (SEC) website.